Genetic clues to irritable bowel syndrome found

Image
Press Trust of India Washington
Last Updated : Mar 22 2014 | 11:26 AM IST
For the first time, scientists have identified a genetic defect that causes a subset of irritable bowel syndrome (IBS), a finding that may help pave way for therapies for the disorder.
Researchers estimate that approximately 15 to 20 per cent of the Western world has IBS, a common disorder that affects the large intestine.
Most patients with the disorder commonly experience symptoms of cramping, abdominal pain, bloating gas, diarrhoea and constipation. Most treatments for IBS target these symptoms.
Researchers found that patients with a subset of IBS have a specific genetic defect, a mutation of the SCN5A gene.
This defect causes patients to have a disruption in bowel function, by affecting the Nav1.5 channel, a sodium channel in the gastrointestinal smooth muscle and pacemaker cells.
The research is in early stages, but the results of this study give researchers hope of finding therapies for these patients.
"This gives us hope that from only treating symptoms of the disease, we can now work to find disease-modifying agents, which is where we really want to be to affect long-term treatment of IBS," said Gianrico Farrugia, a study author, Mayo Clinic gastroenterologist and director of the Mayo Clinic Center for Individualised Medicine.
Researchers studied the sodium channel of 584 people with IBS and 1,380 control subjects. The analysis demonstrated that a defect in the SCN5A gene was found in 2.2 per cent of IBS patients.
The results were confirmed in a genome-wide association study and replicated in 1,745 patients in four independent cohorts of patients with IBS and control subjects.
Additionally, researchers were able to restore function to a patient with constipation predominant IBS with a defective SCN5A gene and resulting abnormally functioning sodium channel.
Researchers used a drug called mexiletine, which restored the function of the channel and reversed the patient's symptoms of constipation and abdominal pain.
The study was published in the journal Gastroenterology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 22 2014 | 11:26 AM IST

Next Story